Kingworld Medicines Group Limited (HKG:1110)

Market Cap	294.80M +14.3%
Revenue (ttm)	1.03B -10.6%
Net Income	5.95M -82.5%
EPS	0.01 -81.8%
Shares Out	589.60M
PE Ratio	47.72
Forward PE	n/a
Dividend	0.03 (6.34%)
Ex-Dividend Date	Jun 5, 2025

Volume	304,000
Average Volume	838,400
Open	0.4950
Previous Close	0.5000
Day's Range	0.4950 - 0.4950
52-Week Range	0.3832 - 0.6500
Beta	0.99
RSI	34.00
Earnings Date	Mar 27, 2026

About Kingworld Medicines Group

Kingworld Medicines Group Limited, an investment holding company, primarily engages in the distribution and sale of branded imported pharmaceutical and healthcare products. The company offers products for relieving cough, alleviating phlegm, soothing asthma, enhancing respiratory system, aiding digestion, promoting intestinal health, activating blood circulation, relieving pain, combating flu, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kingworld Imada Red Flower Oil, Culturelle probiotics product series brands...

• Industry: Pharmaceutical Retailers
• Sector: Healthcare
• Founded: 1996
• Employees: 759
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1110

Financial Performance

In 2024, Kingworld Medicines Group's revenue was 1.06 billion, a decrease of -1.63% compared to the previous year's 1.08 billion. Earnings were 41.56 million, an increase of 9.08%.

Financial numbers in CNY